Should We Treat Minimal/Covert Hepatic Encephalopathy, and with What?
Hepatic encephalopathy exists along a continuum from abnormal neuropsychiatric testing in the absence of clinical findings to varying degrees of detectable clinical findings. The International Society for Hepatic Encephalopathy and Nitrogen Metabolism has endorsed the term "covert" to enco...
Saved in:
Published in | Clinics in liver disease Vol. 19; no. 3; p. 487 |
---|---|
Main Authors | , |
Format | Journal Article |
Language | English |
Published |
United States
01.08.2015
|
Subjects | |
Online Access | Get more information |
Cover
Loading…
Abstract | Hepatic encephalopathy exists along a continuum from abnormal neuropsychiatric testing in the absence of clinical findings to varying degrees of detectable clinical findings. The International Society for Hepatic Encephalopathy and Nitrogen Metabolism has endorsed the term "covert" to encompass minimal hepatic encephalopathy and grade I overt hepatic encephalopathy. Covert hepatic encephalopathy has been associated with poor quality of life, decreased employment, increased falls, and increased traffic accidents that significantly impact quality of life and health care expenditures. Probiotics, nonabsorbable dissacharides, rifaximin, and l-ornithine-l-aspartate have been evaluated with varying levels of success. Because of the lack of universally accepted diagnostic tools, optimal timing of testing and treatment remains controversial. |
---|---|
AbstractList | Hepatic encephalopathy exists along a continuum from abnormal neuropsychiatric testing in the absence of clinical findings to varying degrees of detectable clinical findings. The International Society for Hepatic Encephalopathy and Nitrogen Metabolism has endorsed the term "covert" to encompass minimal hepatic encephalopathy and grade I overt hepatic encephalopathy. Covert hepatic encephalopathy has been associated with poor quality of life, decreased employment, increased falls, and increased traffic accidents that significantly impact quality of life and health care expenditures. Probiotics, nonabsorbable dissacharides, rifaximin, and l-ornithine-l-aspartate have been evaluated with varying levels of success. Because of the lack of universally accepted diagnostic tools, optimal timing of testing and treatment remains controversial. |
Author | Herrera, Jorge L Henderson, Phillip K |
Author_xml | – sequence: 1 givenname: Phillip K surname: Henderson fullname: Henderson, Phillip K organization: Division of Gastroenterology, University of South Alabama, 6000 University Commons, 75 University Boulevard South, Mobile, AL 36688, USA – sequence: 2 givenname: Jorge L surname: Herrera fullname: Herrera, Jorge L email: jherrera@health.southalabama.edu organization: Division of Hepatology, University of South Alabama, 6000 University Commons, 75 University Boulevard South, Mobile, AL 36688, USA. Electronic address: jherrera@health.southalabama.edu |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/26195203$$D View this record in MEDLINE/PubMed |
BookMark | eNo1j91Kw0AUhBdR7I8-gDeyD2DSc052N9krkRKtUPHCSi_LJntKUtIkJKnStzegXg0zHwwzM3FZNzULcYcQIqBZHMK88iEB6hBUCEAXYopax0FCpCZi1vcHGCFYey0mZNBqgmgq0o-iOVVeblluOnaDfCvr8uiqxbL54m6QK27dUOYyrXNuC1c1oy3OD9LVXn6XQyG3hRseb8TV3lU93_7pXHw-p5vlKli_v7wun9ZBrhQOgUYiz5mNsjz24BWDyTHBbB8DZ8SJHSNE1lGkHIEzGq2NjSI0TGRiTXNx_9vbnrIj-13bjVu78-7_D_0A6dVLsA |
CitedBy_id | crossref_primary_10_17116_jnevro2017117101144_147 crossref_primary_10_1016_j_jhep_2016_10_026 crossref_primary_10_3350_cmh_2019_0010n crossref_primary_10_18410_jebmh_2018_522 crossref_primary_10_1007_s11011_016_9878_y crossref_primary_10_1002_14651858_CD011451_pub2 |
ContentType | Journal Article |
Copyright | Copyright © 2015 Elsevier Inc. All rights reserved. |
Copyright_xml | – notice: Copyright © 2015 Elsevier Inc. All rights reserved. |
DBID | CGR CUY CVF ECM EIF NPM |
DOI | 10.1016/j.cld.2015.04.002 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | no_fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1557-8224 |
ExternalDocumentID | 26195203 |
Genre | Journal Article Review |
GroupedDBID | --- .1- .FO 0R~ 1P~ 29B 34G 39C 4.4 457 4CK 5GY 6J9 AAEDT AAEDW AALRI AAQQT AAQXK AAXUO ABFRF ABJNI ABMAC ABOCM ABQZK ACGFS ADBBV ADMUD AEFWE AENEX AEVXI AFCTW AFRHN AFTJW AJUYK ALMA_UNASSIGNED_HOLDINGS AMRAJ ASPBG AVWKF AXIYT AZFZN B08 CGR COIAO CS3 CUY CVF DAHGL DU5 EBS ECM EIF EJD EX3 F5P FDB FEDTE FGOYB HVGLF HZ~ NPM O9- OC. ON0 R2- RIG SEL SES UNMZH WOW Z5R |
ID | FETCH-LOGICAL-c441t-5122deb93bc7d0d4e06c181bf70eb2e89d4e11e5334a20a65199764216e226752 |
IngestDate | Sat Sep 28 08:08:23 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 3 |
Keywords | Minimal hepatic encephalopathy Overt encephalopathy Covert hepatic encephalopathy Encephalopathy |
Language | English |
License | Copyright © 2015 Elsevier Inc. All rights reserved. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c441t-5122deb93bc7d0d4e06c181bf70eb2e89d4e11e5334a20a65199764216e226752 |
PMID | 26195203 |
ParticipantIDs | pubmed_primary_26195203 |
PublicationCentury | 2000 |
PublicationDate | 2015-08-01 |
PublicationDateYYYYMMDD | 2015-08-01 |
PublicationDate_xml | – month: 08 year: 2015 text: 2015-08-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Clinics in liver disease |
PublicationTitleAlternate | Clin Liver Dis |
PublicationYear | 2015 |
SSID | ssj0015099 |
Score | 2.1585617 |
SecondaryResourceType | review_article |
Snippet | Hepatic encephalopathy exists along a continuum from abnormal neuropsychiatric testing in the absence of clinical findings to varying degrees of detectable... |
SourceID | pubmed |
SourceType | Index Database |
StartPage | 487 |
SubjectTerms | Dipeptides - therapeutic use Gastrointestinal Agents - therapeutic use Hepatic Encephalopathy - drug therapy Humans Lactulose - therapeutic use Patient Selection Probiotics - therapeutic use Rifamycins - therapeutic use Severity of Illness Index Sickness Impact Profile |
Title | Should We Treat Minimal/Covert Hepatic Encephalopathy, and with What? |
URI | https://www.ncbi.nlm.nih.gov/pubmed/26195203 |
Volume | 19 |
hasFullText | |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnZ3JSwMxFMZDqyBexH2XHLzV0dkyy0mktFShvVixtzKZecVKN8p40L_e95J0cVRcLkNJaCnzm0leXr73hbHzOPHiKPAcK4gpW9XLwJL0PiaiBw44fuar1ECzFTQe_LuO6JRKt0uqpZdcXqZvX9aV_IcqtiFXqpL9A9n5j2IDfka-eEXCeP0V4_snOqC68giVtlrpN_uj_pAc_OtVUmbmOKlMlCNrjWoTn5LBmA4gfp0pNlUOlry7C-o-7RWqhLIDkm0Ud3Ea6vg5U6plthMW6dIGTKcw1RJcyrebugaTWXDEXNeGE4MZDQVOYa4ucp4Pl_HSY-EtjX2-njk_jck6PfB8mQ7ImdURylpWlVnnS4wmQwWJFnTCVbYHP_QWbLJnXWVWDiMa6lqUtjHbSRgVxbMtbSXuK_wXsoQ23y8sL1SY0d5kG2Z9wG807C1WgtE2W2saBcQOq2nm_BG4Ys4N8ytNnBvi_CPxC468OfHmxPt6lz3Ua-1qwzJHYVgpxqu5hWGZm4GMPZmGmZ35YAcpxmayF9ogXYhibHIcoLrqxLWTQJB-iGqYA8D4OhTuHlsZjUdwwLjnpoGXRjaEGfiJl0rpyTgDVyYRdiTikO3rG9CdaL-T7uzWHH3bc8zWFw_QCVvt4QsGpxit5fJMkXgHkTU7Mw |
link.rule.ids | 786 |
linkProvider | National Library of Medicine |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Should+We+Treat+Minimal%2FCovert+Hepatic+Encephalopathy%2C+and+with+What%3F&rft.jtitle=Clinics+in+liver+disease&rft.au=Henderson%2C+Phillip+K&rft.au=Herrera%2C+Jorge+L&rft.date=2015-08-01&rft.eissn=1557-8224&rft.volume=19&rft.issue=3&rft.spage=487&rft_id=info:doi/10.1016%2Fj.cld.2015.04.002&rft_id=info%3Apmid%2F26195203&rft_id=info%3Apmid%2F26195203&rft.externalDocID=26195203 |